Dr. Eduardo Rego graduated in Medicine from the Faculty of Medicine of Ribeirão Preto at the University of São Paulo (USP) in 1988 and obtained his doctorate from the same institution in 1997. He then did his post-doctorate at Memorial Sloan Kettering Cancer Center in New York (1998-2001) in the laboratory of Dr. Pier Paolo Pandolfi and published several works on the molecular bases of acute promyelocytic leukemia, with emphasis on his articles in the journals PNAS (2000); J Exp Med (2001), Science (2003) and Nature (2008). He was approved in the competition for Full Professor at FMRP-USP in 2010, where he worked until 2018. He is currently Full Professor at the Faculty of Medicine of USP (FM-USP), Coordinator of the Acute Leukemia Service at the Cancer Institute of the State of São Paulo (ICESP) and coordenates the Hematology Services of Rede D'Or and is a Researcher at the D'Or Institute for Research and Education (IDOR). His areas of interest are hematological neoplasms, with special emphasis on the study of pathophysiology and the development of new treatment strategies for acute leukemias. He was one of the founding members of the International Acute Leukemia Consortium (ICAL) of the American Society of Hematology, which develops studies clinical and translational studies on acute leukemias. The Prof. Rego was the President of the International Membership Committee of the American Society of Hematology (2020-2024) and is the Vice President of the Brazilian Association of Hematology and Hemotherapy. He is the Senior Editor of the Brazilian Journal of Medical and Biological Research and Editor of the Hematology, Transfusion and Cell Therapy Journal (HTCT) and Associate Editor of the Annals of Hematology. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The Project "Scientific EMU: Acquisition of a spectral cell sorter for multidimensional characterization of the interactions of hematopoietic cells with the medullary microenvironment in malignant and infectious diseases" aims to allow analyzes of cellular interaction and immuno-phenotypic characterization, either in blood tissue or in tissues of greater structural complexity. The equipme…
The Nucleus of Cellular Therapy - NuTeC will be founded on the union of the Regional Blood Center of Ribeirão Preto (Hemocentro RP) and Butantan. Hemocentro RP expertise in cellular therapy will be added to Butantan excellence in the development and production of health applied products to develop CAR T cell therapy. The activities to be conducted by NuTeC are aligned with the scope of th…
The present proposal establishes the continuity and expansion of the activities of the National Institute of Science and Technology in Stem Cells and Cell Therapy, one of the National Institutes of Science and Technology created by CNPq/FAPESP in 2008. In that opportunity, we proposed the development of an extensive program of basic and clinical research to understand, isolate, culture an…
(Only some records are available in English at this moment)
The description that post-sepsis patients develop immunosuppression has risen the interestabout this phenomenon. Recently, it has been established the role of T regulator lymphocytes, as well anti-inflammatory cytokines and alternatively activated macrophage. In that phase,established cancer could expand, possibly worsening outcomes. Tumor-associatedmacrophages (TAM) are key pieces in orc…
Because of their similarity to hematopoietic stem cells (HSCs), the immature progenitor cells seen in malignant tumors and the various forms of leukemia have been designated cancer stem cells (CSCs). The CSCs are capable of dividing asymmetrically, giving rise to tumor cells that are more differentiated or to identical daughter cells. Because they can repopulate the tumor after chemothera…
(Only some records are available in English at this moment)
Acute Myeloid Leukemia (AML) is the most prevalent bone marrow cancer in Brazil, presenting a significant and challenging health issue due to its broad clinical and molecular variability. This makes precise risk stratification essential for guiding appropriate treatment. Traditional therapies, which combine cytarabine and anthracyclines, remain predominant. However, the heterogeneity of A…
The research project aims to develop an ex vivo platform to assess the effectiveness of drugs in samples from adult patients with acute lymphoblastic leukemia (ALL) within the context of a clinical study. The goal is to correlate drug responses with genetic, proteomic, metabolic, and clinical-laboratory characteristics. Peripheral blood and bone marrow samples from ALL patients diagnosed …
(Only some records are available in English at this moment)
The etiology of Acute Lymphoblastic Leukemia (ALL) is not well established and complex interactions may be involved. Recently, the World Health Organization (WHO) has recognized the Philadelphia-like ALL (Ph-like) as a new provisional diagnostic entity that has a molecular signature similar to ALL Ph+ (BCR-ABL1 +) and is associated with an unfavorable prognosis. Some recurrent genetic alt…
Among myeloid neoplasms, acute myeloid leukemia (AML) is a heterogeneous group of clonal bone marrow diseases that affect hematopoietic progenitors making them unable to differentiate terminally and to respond to natural regulators of cell death and proliferation. The bone marrow microenvironment acts as an important factor in the development, progression, maintenance and evolution of AML…
The present study aims to characterize and analyze the episodes of febrile neutropenia, infectious agents, treatment phase, prophylaxis, mortality and the causes of death after the first induction of remission, in patients affected by acute myeloid leukemia, from secondary data of the Hospital das Clínicas of the Medical School of Ribeirão Preto-USP, from 2012 to 2017. This is a retrospec…
(Only some records are available in English at this moment)
Acute myeloid leukaemia (AML) is a malignant haematological disorder caused by uncontrolled proliferation and impaired differentiation of myeloid progenitor cells. Recent studies suggest that not only intrinsic mutations drive leukemogenesis but that the bone marrow (BM) microenvironment can facilitate the expansion of leukemic cells. Hence, new therapeutic approaches that target both the…
Acute myeloid leukemia (AML) is an aggressive disease with dismal clinical outcome primarily affecting older individuals, frequently unsuitable for intensive chemotherapy. Current, non-intensive chemotherapeutic options, include hypomethylating agents and low-dose of cytarabine, while the differentiation agent all trans retinoic acid (ATRA) has shown success exclusively in acute promyeloc…
Current murine xenotransplantation models used as in vivo study models of human leukemic processes have failed to reconstruct disease-related pathophysiological processes due to non-similarity to the human bone marrow niche. Thus, the evaluation of the high-renewal, differentiation and transformation processes of human hematopoietic stem cells (HSCs) and leukemic (LSCs), as well as their …
(Only some records are available in English at this moment)
| 4 / 4 | Ongoing grants |
| 6 / 5 | Completed research grants |
| 9 / 9 | Ongoing scholarships in Brazil |
| 36 / 17 | Completed scholarships in Brazil |
| 7 / 6 | Completed scholarships abroad |
| 62 / 41 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID